Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases - Summary - MDSpire

Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases

  • By

  • Armelle Otiniano

  • Zoe van de Wyngaert

  • Eolia Brissot

  • Rémy Dulery

  • Joel Gozlan

  • Anne Daguenel

  • Yasmine Abi Aad

  • Laure Ricard

  • Nicolas Stocker

  • Anne Banet

  • Agnes Bonnin

  • Tamim Alsuliman

  • Zora Marjanovic

  • Aurélie Schnuriger

  • Paul Coppo

  • Ollivier Legrand

  • Karine Lacombe

  • Mohamad Mohty

  • Florent Malard

  • December 8, 2022

  • 0 min

Share

Objective:

To analyze clinical outcomes in patients with haematologic malignancies treated with tixagevimab-cilgavimab for Omicron SARS-CoV-2 infection from January to July 2022.

Key Findings:
  • Median patient age was 67 years; most had a history of chemotherapy.
  • Patients had low anti-S IgG levels at diagnosis, indicating weak immune response.
  • Tixagevimab-cilgavimab administration led to a significant increase in anti-S IgG levels.
  • Asymptomatic patients treated early recovered without severe COVID-19 progression.
  • Three symptomatic patients worsened after initial improvement, leading to death, highlighting the need for careful monitoring.
Interpretation:

Tixagevimab-cilgavimab may be effective in preventing severe COVID-19 progression in high-risk patients with hematologic malignancies, even when administered after infection diagnosis, suggesting potential for clinical application.

Limitations:
  • Small and heterogeneous patient population.
  • Lack of data on tixagevimab-cilgavimab efficacy specifically in hematologic malignancies, and potential biases inherent in retrospective studies.
Conclusion:

This study suggests that tixagevimab-cilgavimab can be beneficial in managing Omicron SARS-CoV-2 infection in patients with hematologic malignancies, particularly in asymptomatic cases, but further research is needed to validate these findings.

Original Source(s)

Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases

  • by Armelle Otiniano, Zoe van de Wyngaert, Eolia Brissot, Rémy Dulery, Joel Gozlan, Anne Daguenel, Yasmine Abi Aad, Laure Ricard, Nicolas Stocker, Anne Banet, Agnes Bonnin, Tamim Alsuliman, Zora Marjanovic, Aurélie Schnuriger, Paul Coppo, Ollivier Legrand, Karine Lacombe, Mohamad Mohty, Florent Malard

  • December 8, 2022

Related Content

Prospective systematic classification of causes of death in the course of multiple myeloma

Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro

The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Award Winners (O001-O008)

  • November 9, 2023